Immunolight, LLC

Duke University

Wayne F Beyer, Jr

Harold Walder

Zakaryae Fathi

Frederic Avery Bourke, Jr

Mark Oldham

Justus Adamson

Neil Lee Spector

Mark DeWhirst

Paul Yoon

Michael Nolan

Eric John Toone

Mark W Dewhirst

David M Gooden

Takuya Osada

Ronald A Rudder

Leihua Liu

David Alcorta

Wenle Xia

Kim Lyerly

Erik J Soderblom

Frederic A Bourke

A method for treating a disease in a subject in need thereof is provided involving infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into a diseased site in the subject; and delivering a dose of x-rays to the subject for production of the ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose including a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor, wherein the phosphor-containing drug activator includes an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; the two or more phosphors including ZnSiO:Mnand (3Ca(PO)Ca(F, Cl):Sb, Mn) at a ratio (ZnSiO:Mn):(3Ca(PO)Ca(F, Cl):Sb, Mn)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating or a diamond-like carbon coating.

Phosphor-containing drug activator, suspension thereof, system containing the suspension, and methods for use

A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body;

X-ray psoralen activated cancer therapy (X-PACT)

A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

Tumor imaging with x-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties

Methods of treating a subject are provided, involving providing a first region of biological material coupled to the subject; initiating a change in a cellular environment of the cells in the first region; and due to a change in biological or chemical activity of the cells in the first region, inducing a biological change in a second region inside the subject, along with various biophoton collectors and biophoton bypasses useful for implementing a variety of the method embodiments.

Methods, devices, and compositions for measuring and inducing cell-to-cell communication, and therapeutic uses thereof

A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

Methods for radiotherapy to trigger light activation drugs

A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

Phosphor composition having selected surface coatings

Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

Growing community of inventors

Ivanhoe, VA, United States of America

Wayne F Beyer, Jr